Reports
Subscribe to
our newsletters!
Showing 21–40 of 83 resultsSorted by latest
- This product provides basic information on immunotherapeutics on the market and in R&D targeting nectin-4€ 200.00
- This product provides basic information on approved products and R&D candidates targeting FcRn.€ 200.00
- This product provides basic information on immunotherapy candidates in research and development targeting DLL3.€ 200.00
- This product provides basic information on immunotherapy candidates in research and development targeting B7-H3.€ 300.00
- This product provides basic information on antibody therapy candidates in R&D targeting EpCAM.€ 200.00
- This product provides basic information on antibody therapy candidates in R&D targeting PD-1.€ 200.00
- This product provides basic information on antibody therapy candidates in R&D targeting c-Met.€ 300.00
- This product provides basic information on approved therapeutics and therapy candidates in R&D targeting PSMA.€ 400.00
- This product provides basic information on immunotherapy candidates in research and development targeting mesothelin€ 300.00
- This product provides basic information on therapeutic antibodies in R&D targeting C-C chemokine receptor type 8 (CCR8).€ 300.00
- This product provides basic information on drug candidates in research and development targeting CD40 or CD40 ligand€ 300.00
- This product provides basic information on drug & imaging candidates in R&D targeting Fibroblast Activation Protein (FAP)€ 300.00
- This product provides basic information on approved drugs and drug candidates in R&D targeting folate receptor alpha (FRα)€ 300.00
- This product provides basic information on approved drugs and immunotherapy candidates in R&D targeting IGF-1 or its receptor (IGF-1R)€ 300.00
- This report provides a landscape description and analysis of discovery and development of claudin 18.2 (CLDN18.2)-targeted antibody and cell therapy candidates from an industry perspective as of August 2023Original price was: € 2150.00.€ 1720.00Current price is: € 1720.00.
- This product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Prolia & Xgeva (denosumab).€ 300.00
- This report provides a competitor evaluation in the field of antibodies, proteins, peptides, RNA and small molecules acting as inibitors of complement C5 or antagonists of the C5a receptor€ 400.00
- This product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Humira (adalimumab).€ 400.00
- This product provides basic information on approved drugs and drug candidates in R&D as biosimilar or biosuperior antibodies of Soliris (eculizumab).€ 300.00
- This product provides basic information on approved drugs and drug candidates in R&D as biosimilar or biosuperior antibodies of Xolair (omalizumab).€ 300.00